What alternatives to first-line therapy for depression are effective?

Journal of Clinical Psychiatry

Volumn 71, Issue SUPPL. 1, 2010, Pages 10-15

  Manning, J Sloan ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; APLENZIN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; CONJUGATED ESTROGEN; DESIPRAMINE; DEXAMPHETAMINE; ESCITALOPRAM; ESTROGEN; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; IMIPRAMINE; LIOTHYRONINE; LIOTHYRONINE SODIUM; LITHIUM; LITHIUM CARBONATE; METHAMPHETAMINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NORPAMIN; NORTRIPTYLINE; OLANZAPINE; OLEPTRO; PAROXETINE; PEMOLINE; PINDOLOL; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE;

AKATHISIA; CLINICAL TRIAL; DEPRESSION; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG USE; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; PATIENT EDUCATION; PRIORITY JOURNAL; REMISSION; RESTLESSNESS; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY; HUMANS; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 78149327132     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.9104su1c.02     Document Type: Review

References (25)

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.176/api.ajp.163.1.1905 PubMed
2. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1-2):83-91. doi:10.1016/S0924-97X(98)04-2 PubMed
3. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, pt 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59(11):608-619. PubMed
4. Thase ME. Update on partial response in depression. J Clin Psychiatry. 2009;70(suppl 6):4-9. doi:10.408/JCP.813su1c.01 PubMed
5. Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-647. PubMed
6. Weissman MM, Pilowsky DJ, Wickramaratne PJ, et al for the STAR*D-Child Team. Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA. 2006;295(12):1389-1398. doi:10.101/jama.295.12.1389 PubMed
7. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. doi:10.1016/S06-323(02)0186-8 PubMed
8. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi:10.1046/j.1525-1497.201.01609606.x PubMed
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
10. American Psychiatric Association. Global Assessment of Functioning (GAF) Scale. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:34.
11. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27(2):93-105. PubMed
12. McIntyre RS. When should you move beyond first-line therapy for depression? J Clin Psychiatry. 2010;71(suppl 1):16-20.
13. Maes M. "Functional" or "psychosomatic" symptoms, eg a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuroendocrinol Lett. 2009;30(5):564-573. PubMed
14. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology. 2007;32(12):2479-2489. doi:10.1038/sj.np.1301390 PubMed
15. Gaynes BN. Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. J Clin Psychiatry. 2009; 70(suppl 6):10-15. doi:10.408/JCP.813su1c.02 PubMed
16. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449-459. doi:10.107/s1920-07-061-3 PubMed
17. Candy B, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev. 2008;(2):CD006722.
18. Shelton RC, Osuntokun O, Heinloth AN, et al. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2):131-161. doi:10.2165/1530280-0-0 PubMed
19. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853. doi:10.408/JCP.v68n0604 PubMed
20. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165. doi:10.1097/JCP.0b013e3181674f9 PubMed
21. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206. PubMed
22. Nelson JC, Mankoski R, Baker RA, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord. 2010;120(1-3):133-140. doi:10.1016/j.jad.209.06.026 PubMed
23. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540-549. doi:10.408/JCP.08m04629 PubMed
24. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study (published online ahead of print Feb 23, 2010). Int J Neuropsychopharmacol. doi:10.1017/S14614571015 PubMed
25. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry. 2009;70(3):387-396. doi:10.408/JCP.08m04064 PubMed